Reform Vs. Improvements: No Decision Yet On Fate Of EU Advanced Therapies Law
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory framework for gene therapy and tissue-engineered products is seen as inflexible and unclear, but policymakers have yet to decide on whether to fix what's there or aim for a legislative change.
You may also be interested in...
EMA's Action Plan To Support ATMPs Expected In Jan 2017
The European Medicines Agency's action plan to support the development of advanced therapy medicinal products will prioritize on actions that are feasible, will result in major gains without the need for a lot of effort and will not require legislative changes.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.